Analysis of clinical outcome according to immunohistochemically defined GC and non-GC phenotypes for rituximab and control groups
| Survival . | Rituximab . | Control . | ||||||
|---|---|---|---|---|---|---|---|---|
| All, % . | GC, % . | Non-GC, % . | P . | All, % . | GC, % . | Non-GC, % . | P . | |
| OS | 76 | 77 | 76 | .936 | 57 | 70 | 47 | .012 |
| FFS | 67 | 68 | 63 | .593 | 43 | 59 | 30 | .001 |
| Survival . | Rituximab . | Control . | ||||||
|---|---|---|---|---|---|---|---|---|
| All, % . | GC, % . | Non-GC, % . | P . | All, % . | GC, % . | Non-GC, % . | P . | |
| OS | 76 | 77 | 76 | .936 | 57 | 70 | 47 | .012 |
| FFS | 67 | 68 | 63 | .593 | 43 | 59 | 30 | .001 |
Cumulative survival was estimated by Kaplan-Meier method. The significance of the differences was analyzed by log-rank test. The values represent the percentage of surviving patients after follow-up of 27 months.